ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: 0141 • ACR Convergence 2025

    Cytokine profiles in antiphospholipid syndrome

    Xiangjun Liu1, Yuzhou Gan2, Chun Li3, Jianping Guo4, lei zhu5 and yuan jia3, 1Peking University, Beijing, Beijing, China, 2University of Michigan, Ann Arbor, MI, 3Peking University People's Hospital, Beijing, China (People's Republic), 4Peking University People's Hospital, Beijing, Beijing, China, 5Affiliated Nantong Rehabilitation Hospital of Nantong University, Nantong, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with unknown etiology. Inflammatory-mediated tissue damage plays an important role in APS. This study aimed to investigate…
  • Abstract Number: 2035 • ACR Convergence 2025

    Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease

    Joshua Friedman1, JD Lu2, Bing Wang2, Kinjal Hew2, Preeyam Patel2, Michael Kennedy2, Mark Rose2, Curtis Sheldon2, Rachel McLean2, Emily Svejnoha2, MiRa Huyghe1, Brian Connolly2 and Deanna Nguyen2, 1Spyre Therapeutics, Waltham, MA, 2Spyre Therapeutics, Waltham

    Background/Purpose: TL1A is an inflammatory cytokine and a member of the TNF superfamily. Target cells that express DR3 and respond to TL1A include T cells,…
  • Abstract Number: 1622 • ACR Convergence 2025

    Defective CD4+ regulatory T cells in active Takayasu arteritis patients can be improved by efficiency treatment of tofacitinib

    jing luo1 and Lan He2, 1the first affiliated hospital of xi'an jiaotong university, xi'an, China (People's Republic), 2The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic)

    Background/Purpose: To investigate the efficacy of tofacitinib (TOF) in patients with active TAK, explore the effect on CD4+ regulatory T cells (Tregs) homeostasis and relationship…
  • Abstract Number: 0909 • ACR Convergence 2025

    Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.

    Marcus Hines1, Timothy Borbet2 and Sergei Koralov2, 1New York University Grossman School of Medicine, New York, NY, 2NYU Langone Medical Center, New York

    Background/Purpose: The microRNA(miR)29 family is encoded by two separate loci, the miR29ab1 and miR29b2c alleles. We have previously shown that the microRNA(miR)29 family regulates the…
  • Abstract Number: 0109 • ACR Convergence 2025

    Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation

    Juan Liang1 and Yinlian Zhang2, 1Gempharmatech, Nanjing, Jiangsu, China, 2GemPharmatech, Nanjing, China (People's Republic)

    Background/Purpose: Psoriatic arthritis (PsA), a complex inflammatory disorder that affects up to 30% of psoriasis patients. It is marked by clinical heterogeneity and a lack…
  • Abstract Number: 2010 • ACR Convergence 2025

    Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli

    Tony Merriman1, Christopher Hall2, Annie Chien2, Richard Reynolds3, Jeffrey Edberg3, Pariyaphon Lertprachakwong3, Hannah Darroch4, Megan Leask4, Mumin Ozturk5, Brenda Kischkel5, Nicholas Sumpter5, Leo Joosten5 and Nils Asmann5, 1University of Alabama at Birmingham, Homewood, AL, 2University of Aucklabd, Auckland, New Zealand, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Otago, Dunedin, New Zealand, 5Radboud University Medical College, Nijmegen, Netherlands

    Background/Purpose: CSF1 and CSF1R encode a secreted and membrane-bound cytokine and its receptor controlling differentiation of monocytes into macrophages and inflammatory activity of macrophages. There…
  • Abstract Number: 1539 • ACR Convergence 2025

    The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis

    Muhammad Usman Hashmi1, Paramarajan Piranavan2, Yasmeen Sufi3, Zaira Nasir4, Zainab Azhar5, Shamaem Tariq5, Hamas Ul Hudaibia5, IMRAN SAEED6, Aayet Zulfiqar5, Natasha Rasool2 and Anum Faiz7, 1Rahmah Academy of Research Excellence, Islamabad, Pakistan., Islamabad, Pakistan, 2University of Kentucky, Louisville, KY, 3Karachi Medical & Dental College, Karachi, Karachi, Pakistan, 4Rawalpindi Medical University,Rawalpindi, Pakistan., Islamabad, Pakistan, 5Rawalpindi Medical University,Rawalpindi, Pakistan., Rawalpindi, Pakistan, 6Nishtar Medical University,Multan, Pakistan., Multan, Pakistan, 7Jinnah Hospital Lahore, Pakistan, Lahore, Pakistan

    Background/Purpose: Type I interferon (IFN) signaling is central to systemic lupus erythematosus (SLE) pathogenesis, and anifrolumab, a monoclonal antibody targeting the IFN-α receptor (IFNAR), has…
  • Abstract Number: 0903 • ACR Convergence 2025

    Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling

    Catherine Wioland1, Corinne Vedrine2, Caroline Walter1, Fanny Marque2, Thomas Dannequin2, Melanie Cecci1, David Buffet1, Cindy Schmid1, Elena Degl'Innocenti1, Gautier Robert1, Grazyna Wieczorek1, David Schubert1, Catriona Paape1 and Isabelle Isnardi3, 1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, 3Novartis, Gueberschwihr, France

    Background/Purpose: B cells are key players in the pathogenesis of Sjögren’s disease (SjD) and other systemic auto-immune diseases, supporting B cell depletion as an attractive…
  • Abstract Number: 0108 • ACR Convergence 2025

    In Vivo and In Vitro Analysis of IL-23 Modulation Following Anti-TNF Therapy in Psoriatic Arthritis

    Jesús Eduardo Martín Salazar1, Clementina López Medina2, Carlos Pérez Sánchez3, María Ángeles Puche-Larrubia4, Pedro Ortiz Buitrago5, María Dolores López-Montilla6, Iván Arias de la Rosa7, Laura Cuesta López8, Miriam Ruiz Ponce8, Antonio Barranco8, Laura Romero Zurita8, Elena Moreno-Caño9, Rafaela Ortega-Castro10, Jerusalén Calvo11, M Carmen Abalos-Aguilera12, Desiree Ruiz-Vilchez13, Chary López pedrera14, Alejandro Escudero Contreras11, Eduardo Collantes estévez15 and Nuria Barbarroja16, 1Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, 2Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 4Reina Sofia University Hospital, Granada, Spain, 5Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, 6Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, 7IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, 8Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Córdoba, Spain, 9IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 11IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 12Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 13Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 14Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 15Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 16Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease for which TNFα inhibitors are the standard first-line biologic therapy. Nonetheless, a significant proportion of patients…
  • Abstract Number: 1974 • ACR Convergence 2025

    Serial ferritin as a diagnostic surrogate marker in Hemophagocytic Lymphohistiocytosis (HLH), a retrospective single-center study

    Chen Chao1, Anna Lichtiger2, Xianhong Xie3, Melissa Fazzari4 and Ayesha Bibi5, 1Rheumatology Division, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, NY, 2Internal Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, The Bronx, NY, 3Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY, 4Department of Epidemiology & Population Health, Albert Einstein College of Medicine,, Bronx, NY, 5Rheumatology Division, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Woodbridge Township, NJ

    Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by cytokine dysregulation, resulting in multi-organ involvement and high mortality. (1-2) There is a time lag…
  • Abstract Number: 1535 • ACR Convergence 2025

    INB-619 – A Novel Gamma-Delta (γδ) T cell Engager to Target B cells in Autoimmune Diseases

    Lei Ding, Yanjie Li, Mariska ter Haak, Sadhak Sengupta, Kate Rochlin and Lawrence Lamb, IN8bio, Inc., New York, NY

    Background/Purpose: T cell engagers (TCEs) redirect T cells to bind target cells by linking T cells with target-associated antigens expressed on cells responsible for disease…
  • Abstract Number: 0679 • ACR Convergence 2025

    Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation

    Parisa Mazrooei, Xuting Rebecca Sheng, Xiaoyun Yang, Lyrialle Han, Samira Jamalian, Daniel Repplinger, Jingxuan He, Evelin Logis, Jeongsup Shim, Angela Hendricks, Lena Wang, Andrew Thorley and Sara Glickstein, Genentech/Roche, South San Francisco

    Background/Purpose: There are 3 isoforms of Transforming Growth Factor Beta (TGFb), a cytokine frequently upregulated in fibrosis. Chronic targeting of TGFb1 and TGFb2 for fibrotic…
  • Abstract Number: 0105 • ACR Convergence 2025

    Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis

    Guillaume LARID1, Cassandre Dumonteix Moreau2, Adrien JAMAI2, Hanitriniaina Rabeony2, Jean Claude LECRON2, Elisabeth Gervais1, Jean François JEGOU2 and franck MOREL2, 1Poitiers University Hospital - Poitiers University - LITEC Laboratory UR 15560, Poitiers, France, 2Poitiers University - LITEC Laboratory UR 15560, Poitiers, France

    Background/Purpose: Psoriatic disease is a systemic inflammatory condition which encompasses both cutaneous psoriasis (PsO), psoriatic arthritis (PsA) and multiple comorbidities. The chronic Imiquimod (IMQ) induced…
  • Abstract Number: 1842 • ACR Convergence 2025

    Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort

    Melissa Munroe1, Zoe Reed2, Joel Guthridge2, Diane Kamen3, Timothy Niewold4, Kendra Young5, Angel Weng5, Emma Wu5, Gary Gilkeson6, Michael Weisman7, Mariko Ishimori7, Daniel Wallace8, John Harley9, David Karp10, Jill Norris11 and Judith James2, 1Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Medical University of South Carolina, Johns Island, SC, 4Hospital for Special Surgery, New York, New York, 5Colorado School of Public Health, Aurora, CO, 6Medical University of South Carolina, Charleston, SC, 7Cedars-Sinai Medical Center, LOS ANGELES, CA, 8Cedars Sinai Medical Center, Studio City, CA, 9US Department of Veterans Affairs Medical Center, Cincinnati, OH, 10UT Southwestern Medical Center, Dallas, TX, 11Colorado School of Public Health, Denver, CO

    Background/Purpose: Socioeconomic environmental factors are associated with SLE disease activity and early mortality and may contribute to disease progression in at-risk populations. Blood relatives (BRs)…
  • Abstract Number: 1437 • ACR Convergence 2025

    Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications

    Byron Kwan1, Joseph Merola2, Andrew Blauvelt3, Daniel Rios1, Joana Ministro1, Jacob Milligan1, Ghassan Fayad1, Christopher Finch4, Eugenia Levi5, Joseph Senn5, Jason Oh1 and Hussam Shaheen1, 1Paragon Therapeutics, Waltham, MA, 2UT Southwestern Medical Center, Dallas, TX, 3Blauvelt Consulting, LLC, Annapolis, MD, 4Oruka Therapeutics, Menlo Park, CA, 5Oruka Therapeutics, Waltham, MA

    Background/Purpose: Interleukin 17 (IL-17) is a pro-inflammatory cytokine that has been implicated in the pathogenesis of multiple autoimmune conditions, including psoriasis and psoriatic arthritis (PsA).…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 42
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology